Address
999 West Broadway
Vancouver, BC V5Z 1K5
Canada
Phone
17783310962
Website
Sector
Healthcare
Industry
Biotechnology
Employees
35
First IPO Date
March 13, 2015
| Name | Title | Pay | Year Born |
| David Ross Parkinson | President, Chief Executive Officer & Director | 894,018 | 1950 |
| David S. Wood | Chief Financial Officer | 646,765 | 1957 |
| Alessandra Cesano | Chief Medical Officer & Executive Vice President | 678,282 | 1961 |
| Peter A. Virsik | Executive Vice President & Chief Operating Officer | 696,191 | 1971 |
| Erin Rudsinski | Executive | 0 | N/A |
| Neil Thapar | Executive | 0 | N/A |
| Nkengyal Barber | Executive | 0 | N/A |
| Chandtip Chandhasin | Executive | 0 | N/A |
| Loleta Harris | Executive | 0 | N/A |
| Erica Osbourne | Executive | 0 | N/A |
ESSA Pharma Inc. (EPIX) functions as a clinical-stage pharmaceutical firm, concentrating its efforts on developing innovative and exclusive therapies designed to combat prostate cancer. The company's primary drug candidate is EPI-7386, an oral treatment presently undergoing Phase I clinical trials. This investigational compound is intended for individuals suffering from metastatic castration-resistant prostate cancer. Furthermore, ESSA Pharma has established collaborative partnerships with organizations including Caris Life Sciences, Inc., Bayer Consumer Care AG, Janssen Research & Development, LLC, and Astellas Pharma Inc. Founded in 2009, the company's corporate offices are located in Vancouver, Canada.